1-(4-氰基苯基L)-4-哌嗪羧酸乙酯 | 352018-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(4-氰基苯基L)-4-哌嗪羧酸乙酯
• 英文名称: 1-(4-cyanophenyl)-piperidine-4-carboxylic acid ethyl ester
• 英文别名: ethyl 1-(4-cyanophenyl)-piperidine-4-carboxylate；4-(4-ethoxycarbonyl-piperidino)-benzonitrile；Ethyl 1-(4-cyanophenyl)piperidine-4-carboxylate
• CAS: 352018-90-7
• 化学式: C₁₅H₁₈N₂O₂
• mdl: MFCD03086198
• 分子量: 258.32
• InChiKey: LIWHXOHASZYDEM-UHFFFAOYSA-N

物化性质

• 熔点：
  67 °C
• 沸点：
  415.4±40.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.466
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S36/37
• 危险类别码：
  R20/21/22
• 海关编码：
  2933399090
• 危险品运输编号：
  UN 3276

SDS

Name:	Ethyl 1-(4-cyanophenyl)-4-piperidinecarboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	352018-90-7

Section 1 - Chemical Product MSDS Name:Ethyl 1-(4-cyanophenyl)-4-piperidinecarboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
352018-90-7	Ethyl 1-(4-cyanophenyl)-4-piperidineca	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 352018-90-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H18N2O2
Molecular Weight: 258.32

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 352018-90-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 1-(4-cyanophenyl)-4-piperidinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 352018-90-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 352018-90-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 352018-90-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-氰基苯基L)-4-哌嗪羧酸乙酯 在 甲醇 、 氢气 、 1-羟基苯并三唑 、 magnesium 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 51.0h， 生成 tert-butyl N-[[4-[4-[4-(trifluoromethoxy)benzoyl]piperidin-1-yl]phenyl]methyl]carbamate
  参考文献：
  名称：

  [EN] ANTI-INFECTIVE COMPOUNDS
  [FR] COMPOSÉS ANTI-INFECTIEUX

  摘要：

  公开号：

  WO2015014993A3
• 作为产物：
  描述：

  哌啶-4-甲酸乙酯 、 对氟苯腈 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以93%的产率得到1-(4-氰基苯基L)-4-哌嗪羧酸乙酯
  参考文献：
  名称：

  以Cd（II）簇为SBU的三种新型同构配位聚合物：合成，结构表征和发光性能

  摘要：

  三种新的同构配位聚合物{Cd 1.33 L（Cl）0.67（H 2 O）0.67 } n（1），{Cd 1.33 L（Br）0.67（H 2 O）0.67 } n（2）和{Cd 1.33 L（I）0.67（H 2 O）0.67 } n（3），是使用半柔性原位生成的四唑配体合成的。所有配合物在立方空间群P 4 1 32中结晶。1，三镉2+与从三个四唑单元，每个单元两个N原子沿离子形成三核单元，其中每个金属离子另外由羧酸O和μ桥接3个-Cl单元。此Cd（II）簇与配体一起形成一个三角形排列，该排列延伸形成一个二维片材，该片材进一步进行了广泛的互穿，从而生成了一个整体的三维配位聚合物。所有复合物在高达约330°C的温度下都表现出热稳定性，在〜140°C时失去了配位的水分子。在340 nm激发后，配合物表现出固态发光，并在〜415 nm处出现发射峰，随着卤化物阴离子从氯化物变为溴化物变为碘化物，谱带变宽时显示出轻微的红移。

  DOI：

  10.1021/cg201028e

文献信息

• 1,2,4-oxadiazole derivatives and their therapeutic use
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2202232A1

  公开（公告）日：2010-06-30

  New derivatives of general formula (I), or pharmaceutically acceptable salts or N-oxides thereof wherein, A is selected from the group consisting of -N-, -O- and -S-; B and C are independently selected from the group consisting of-N- and -O-, with the proviso that at least two of A, B and C are nitrogen atoms; G1 is selected from the group consisting of -CH2-, -NH- and -O-; G2 is selected from the group consisting of -NR4- and -O-; R1 represents: ➢ a 8 to 10 membered bicyclic N-containing heteroaryl group optionally substituted with a C1-4 carboxyalkyl group or a C1-4 aminoalkyl group, ➢ a pyridyl group optionally substituted with one or more substituents selected from hydroxy groups, C1-4 alkyl groups, C1-4 carboxyalkyl groups, C1-4 haloalkyl groups, C1-4 alkoxy groups, amino groups, C1-4 aminoalkyl groups and C1-4 aminoalkoxy groups, ➢ a pyridone group substituted with one or more C1-4 alkyl groups; C1-4 haloalkyl groups or C1-4 aminoalkyl groups, or ➢ a group of formula: wherein: • Ra represents a hydrogen atom, a halogen atom, a C1-4 alkyl group, C3-4 cycloalkyl group or a -CF3 group; • Rb represents a hydrogen atom, a halogen atom, a C14 alkyl group, a -CF3 group or a C1-4 alkoxy group; • Rd represents a hydrogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; • Rc represents: ○ a hydrogen atom, a C1-4 hydroxyalkyl group, a C1-4 aminoalkyl group which is optionally substituted with one or more substituents selected from halogen atoms, hydroxy groups and -CF3 groups; ○ a 4 to 6-membered saturated N-containing heterocyclic ring optionally substituted with a C1-2 carboxyalkyl group; ○ -(CH2)(0-4)-C(O)OR', -(CH2)(0-4)-C(O)NR'R", -(CH2)(0-4)-NHC(O)R", -S(O)2NR'R", -O-(CH2)(2-4)NR'R", -O-(CH2)(1-4)C(O)OR", -O-(CH2)(1-4)-C(O)NR'R", -(CH2)(0-4)-NR'R", -(CH2)(0-4)-CONHS(O)2R', -(CH2)(0-4)-NHS(O)2R' or -(CH2)(0-3)-N H-(CH2)(1-3)-(NH)(0-1)S(O)2R' wherein, ■ R' represents a hydrogen atom or a C1-4 alkyl group, ■ R" represents a hydrogen atom, a C1-4 alkyl group, a C3-4 cycloalkyl group, a C1-4 carboxyalkyl group, a C1-4 haloalkyl group, a C1-4 hydroxyalkyl group or a 6 membered, saturated N-containing heterocyclic ring, or ■ R' and R" together with the nitrogen atom to which they are attached from a 4 to 6 membered heterocyclic group which contains, as heteroatoms, one N atom and, optionally, one further atom selected from N and O, and which is optionally substituted with a carboxy or a C1-4 carboxyalkyl group, or Rc together with Rd form a C5-6 cycloalkyl group optionally substituted by a -NHRf group, wherein Rf is selected from the group consisting of a hydrogen atom and a carboxymethyl group; R2 and R3 are independently selected from the group consisting of hydrogen atoms, halogen atoms and C1-4 alkyl groups; and R4 is selected from the group consisting of a hydrogen atom, a phenyl group, a C3-4 cycloalkyl-C1-4 alkyl group, C1-4 aminoalkyl group, C1-4 haloalkyl group and a linear or branched C1-4 alkyl group which is optionally substituted by a phenyl or a pyridyl group.

  通用公式（I）的新衍生物，或其药用可接受盐或N-氧化物，其中， A选自-N-，-O-和-S-组成的群; B和C分别选自-N-和-O-组成的群，但至少有两个A，B和C是氮原子; G1选自-CH2-，-NH-和-O-组成的群; G2选自-NR4-和-O-组成的群; R1代表: ➢一个含氮杂环的8到10成员双环基团，可选择地取代为C1-4羧基烷基基团或C1-4氨基烷基基团， ➢一个吡啶基，可选择地取代为一个或多个取代基，所选取代基包括羟基、C1-4烷基基团、C1-4羧基烷基基团、C1-4卤代烷基基团、C1-4烷氧基团、氨基、C1-4氨基烷基基团和C1-4氨氧基团， ➢一个吡啶酮基，取代为一个或多个C1-4烷基基团；C1-4卤代烷基基团或C1-4氨基烷基基团，或 ➢一个公式的基团： 其中: • Ra代表氢原子、卤原子、C1-4烷基基团、C3-4环烷基基团或-CF3基团; • Rb代表氢原子、卤原子、C14烷基基团、-CF3基团或C1-4烷氧基团; • Rd代表氢原子、C1-4烷基基团或C1-4烷氧基团; • Rc代表: ○氢原子、C1-4羟基烷基基团、C1-4氨基烷基基团，可选择地取代为一个或多个取代基，所选取代基包括卤原子、羟基和-CF3基团; ○一个4到6成员饱和的含氮杂环环，可选择地取代为C1-2羧基烷基基团; ○-(CH2)(0-4)-C(O)OR'，-(CH2)(0-4)-C(O)NR'R"，-(CH2)(0-4)-NHC(O)R"，-S(O)2NR'R"，-O-(CH2)(2-4)NR'R"，-O-(CH2)(1-4)C(O)OR"，-O-(CH2)(1-4)-C(O)NR'R"，-(CH2)(0-4)-NR'R"，-(CH2)(0-4)-CONHS(O)2R'，-(CH2)(0-4)-NHS(O)2R'或-(CH2)(0-3)-N H-(CH2)(1-3)-(NH)(0-1)S(O)2R'其中， ■ R'代表氢原子或C1-4烷基基团， ■ R"代表氢原子、C1-4烷基基团、C3-4环烷基基团、C1-4羧基烷基基团、C1-4卤代烷基基团、C1-4羟基烷基基团或6成员饱和的含氮杂环环，或 ■ R'和R"与它们连接的氮原子一起形成一个4到6成员的杂环基团，该基团包含一个N原子和可选择地一个进一步选择自N和O的原子，并可选择地取代为羧基或C1-4羧基烷基基团， 或Rc与Rd一起形成一个可选择地由-NHRf基团取代的C5-6环烷基基团，其中Rf选自氢原子和羧甲基基团; R2和R3分别选自氢原子、卤原子和C1-4烷基基团;和 R4选自氢原子、苯基团、C3-4环烷基-C1-4烷基基团、C1-4氨基烷基基团、C1-4卤代烷基基团和可选择地由苯基或吡啶基取代的线性或支链C1-4烷基基团。
• [EN] PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES<br/>[FR] DERIVES DE PIPERAZINE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET PSYCHIATRIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2004101546A1

  公开（公告）日：2004-11-25

  The present invention relates to novel piperidine carbonyl piperazine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型哌啶羰基哌嗪衍生物，其制备方法，含有它们的组合物，以及它们在治疗神经和精神疾病中的用途。
• Use of substituted 2 phenylbenzimidazoles as medicaments
  申请人：Streicher Ruediger

  公开号：US20050014810A1

  公开（公告）日：2005-01-20

  The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R 1 is a group of formula

  本发明涉及使用式I的取代2-苯基苯并咪唑，其中R1、R2、R3、R4、R5和m具有权利要求中给出的含义，用于制备治疗或预防涉及胰高血糖素受体疾病的药物，以及式I的新化合物，其中R1是一个公式的基团。
• [DE] VERWENDUNG VON SUBSTITUIERTEN 2-PHENYLBENZIMIDAZOLEN ALS ARZNEIMITTEL<br/>[EN] USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS<br/>[FR] UTILISATION DE 2-PHENYLBENZIMIDAZOLES SUBSTITUES EN TANT QUE MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2004062663A1

  公开（公告）日：2004-07-29

  Die vorliegende Erfindung betrifft die Verwendung eines substituierten 2-Phenylbenzimidazols der Formel (I), worin R1, R2, R3, R4, R5 und m die in den Ansprüchen angegebenen Bedeutungen aufweisen, für die Herstellung eines Medikamentes zur Behandlung oder Vorbeugung von Krankheiten, bei denen Glucagon Rezeptoren beteiligt sind, sowie neue Verbindungen der Formel (I), worin R1 ein Dehydroabietyl-Rest der Formel (II) ist.

  这项发明涉及使用式（I）的取代2-苯基苯并咪唑，其中R1、R2、R3、R4、R5和m具有权利要求中所述的含义，用于制备一种药物，用于治疗或预防涉及胰高血糖素受体的疾病，以及式（I）中R1为式（II）的脱氢松香烯基团的新化合物。
• Electrochemical Cross-Dehydrogenative Aromatization Protocol for the Synthesis of Aromatic Amines
  作者：Shao-Kun Tao、Shan-Yong Chen、Mei-Lin Feng、Jia-Qi Xu、Mao-Lin Yuan、Hai-Yan Fu、Rui-Xiang Li、Hua Chen、Xue-Li Zheng、Xiao-Qi Yu

  DOI：10.1021/acs.orglett.1c04129

  日期：2022.2.4

  The introduction of amines onto aromatics without metal catalysts and chemical oxidants is synthetically challenging. Herein, we report the first example of an electrochemical cross-dehydrogenative aromatization (ECDA) reaction of saturated cyclohexanones and amines to construct anilines without additional metal catalysts and chemical oxidants. This reaction exhibits a broad scope of cyclohexanones

  在没有金属催化剂和化学氧化剂的情况下将胺引入芳烃中是一项综合挑战。在这里，我们报告了饱和环己酮和胺的电化学交叉脱氢芳构化 (ECDA) 反应在没有额外金属催化剂和化学氧化剂的情况下构建苯胺的第一个例子。该反应展示了包括杂环酮在内的广泛的环己酮，提供了多种具有不同功能的芳香胺，在生物活性化合物的合成中显示出巨大的潜力。